Neuropsychiatric Lupus: Clinical and imaging aspects

Bulletin of the NYU Hospital for Joint Diseases

Volumn 65, Issue 3, 2007, Pages 194-199

  Brey, Robin L ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CYTOKINE; FLUORO 2 DEOXY DEXTRO GLUCOSE; FLUORODEOXYGLUCOSE; IMMUNOSUPPRESSIVE AGENT; PHOSPHOLIPID ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY PRODUCTION; ATHEROSCLEROSIS; BLOOD BRAIN BARRIER; BRAIN ATROPHY; BRAIN METABOLISM; CHILD HEALTH; COGNITIVE DEFECT; DISEASE ASSOCIATION; HUMAN; LABORATORY TEST; MENTAL DISEASE; MICROANGIOPATHY; MORBIDITY; MORTALITY; NEUROIMAGING; NEUROLOGIC DISEASE; NEUROPSYCHIATRIC LUPUS; NEUROPSYCHOLOGICAL TEST; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; PREVALENCE; QUALITY OF LIFE; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYSTEMIC LUPUS ERYTHEMATOSUS; WHITE MATTER; ANIMAL; BRAIN; BRAIN VASCULITIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; SENSITIVITY AND SPECIFICITY;

ANIMALS; BRAIN; COGNITION DISORDERS; HUMANS; LUPUS VASCULITIS, CENTRAL NERVOUS SYSTEM; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 38449095945     PISSN: 19369719     EISSN: 19369727     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Ward MM. Prevalence of physician-diagnosed systemic lupus erythematosus in the United States: Results from the third national health and nutrition examination survey. Journal of Women's Health. 2004;13:713-8.
2. Danchenko N, Satia JA, Anthony MS. Epidemiology of systemic lupus erythematosus: A comparison of worldwide disease burden. Lupus. 2006;15:308-18.
3. Ainiala H, Loukkola J, Peltola J, et al. The prevalence of neuropsychiatric syndromes in systemic lupus erythematosus. Neurology. 2001;57:496-500.
4. Brey RL, Holliday SL, Saklad AR, et al. Neuropsychiatric syndromes in lupus: Prevalence using standardized definitions. Neurology. 2002;58:1214-20.
5. McLaurin EY, Holliday SL, Williams P, Brey RL. Predictors of cognitive dysfunction in patients with systemic lupus erythematosus. Neurology. 2005;64:297-303.
6. Mikdashi J, Handwerger B. Predictors of neuropsychiatric damage in systemic lupus erythematosus: Data from the maryland lupus cohort. Rheumatology. 2004;43:1555-60.
7. Hanly JG, McCurdy G, Fougere L, et al. Neuropsychiatric events in systemic lupus erythematosus: Attribution and clinical significance.see comment. J Rheumatol. 2004;31:2156-62.
8. Harel L, Sandborg C, Lee T, von Scheven E. Neuropsychiatric manifestations in pediatric systemic lupus erythematosus and association with antiphospholipid antibodies. J Rheumatol. 2006;33:1873-7.
9. Hanly JG, Urowitz MB, Sanchez-Guerrero J, et al. Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: An international inception cohort study. Arthritis & Rheumatism. 2007;56:265-73.
10. Sibbitt WL Jr, Brandt JR, Johnson CR, et al. The incidence and prevalence of neuropsychiatric syndromes in pediatric onset systemic lupus erythematosus. J Rheumatol. 2002;29:1536-42.
11. Yu HH, Lee JH, Wang LC, et al. Neuropsychiatric manifestations in pediatric systemic lupus erythematosus: A 20-year study. Lupus. 2006;15:651-7.
12. Bernatsky S, Clarke A, Gladman DD, et al. Mortality related to cerebrovascular disease in systemic lupus erythematosus. Lupus. 2006;15:835-9.
13. Rivest C, Lew RA, Welsing PM, et al. Association between clinical factors, socioeconomic status, and organ damage in recent onset systemic lupus erythematosus. J Rheumatol. 2000;27:680-4.
14. Sibbitt WL Jr, Sibbitt RR, Brooks WM. Neuroimaging in neuropsychiatric systemic lupus erythematosus.[see comment]. Arthritis Rheum. 1999;42:2026-38.
15. Shimojima Y, Matsuda M, Gono T, et al. Relationship between clinical factors and neuropsychiatric manifestations in systemic lupus erythematosus. Clin Rheumatol. 2005;24:469-75.
16. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum. 1999;42:599-608.
17. Costallat L, Bertolo M, Appenzeller S. The american college of rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes: Analysis of 527 patients. Lupus. 2001;10:S32.
18. Kozora E, Ellison MC, West S. Depression, fatigue, and pain in systemic lupus erythematosus (SLE): Relationship to the american college of rheumatology SLE neuropsychological battery. Arthritis Rheum. 2006;55:628-35.
19. Haupt M, Millen S, Janner M, etet al. Improvement of coping abilities in patients with systemic lupus erythematosus: A prospective study. Ann Rheum Dis. 2005;64:1618-23.
20. Hanly JG. Neuropsychiatric lupus. Curr Rheumatol Rep. 2001;3:205-212.
21. Hanly JG, Walsh NM, Sangalang V. Brain pathology in systemic lupus erythematosus. J Rheumatol. 1992;19:732-41.
22. Belmont HM, Abramson SB, Lie JT. Pathology and pathogenesis of vascular injury in systemic lupus erythematosus, interactions of inflammatory cells and activated endothelium. Arthritis Rheum. 1996;39:9-22.
23. Gonzalez-Crespo MR, Blanco FJ, Ramos A, et al. Magnetic resonance imaging of the brain in systemic lupus erythematosus. Br J Rheumatol. 1995;34:1055-60.
24. Karassa FB, Ioannidis JP, Boki KA, et al. Predictors of clinical outcome and radiologic progression in patients with neuropsychiatric manifestations of systemic lupus erythematosus. Am J Med. 2000;109:628-34.
25. Abbott NJ, Mendonca LL, Dolman DE. The blood-brain barrier in systemic lupus erythematosus. Lupus. 2003;12:908-15.
26. Zaccagni H, Fried J, Cornell J, et al. Soluble adhesion molecule levels, neuropsychiatric lupus and lupus-related damage. Frontiers in Bioscience. 2004;9:1654-9.
27. Matsuda J, Gohchi K, Gotoh M, et al. Circulating intercellular adhesion molecule-1 and soluble interleukin 2-receptor in patients with systemic lupus erythematosus. Eur J Haematol. 1994;52:302-3.
28. Sfikakis PP, Charalambopoulos D, Vayiopoulos G, et al. Increased levels of intercellular adhesion molecule-1 in the serum of patients with systemic lupus erythematosus. Clin Exp Rheumatol. 1994;12:5-9.
29. Spronk PE, Bootsma H, Huitema MG, et al. Levels of soluble VCAM-1, soluble ICAM-1, and soluble E-selectin during disease exacerbations in patients with systemic lupus erythematosus (SLE); a long term prospective study. Clin Exp Rheumatol. 1994;97:439-44.
30. Pierangeli SS, Harris EN. Antiphospholipid antibodies in an in vivo thrombosis model in mice. Lupus. 1994;3:247-51.
31. DeGiorgio LA, Konstantinov KN, Lee SC, et al. A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus.[see comment]. Nat Med. 2001;7:1189-93.
32. Husebye ES, Sthoeger ZM, Dayan M, et al. Autoantibodies to a NR2A peptide of the glutamate/NMDA receptor in sera of patients with systemic lupus erythematosus. Ann Rheum Dis. 2005;64:1210-3.
33. Omdal R, Brokstad K, Waterloo K, et al. Neuropsychiatrice disturbances in SLE are associated with antibodies against NMDA receptors. European Journal of Neurology. 2005;12:392-8.
34. Harrison M, Ravdin L, Volpe B, et al. Anti-NR2 antibody does not identify cognitive impairment in a general SLE population. Arthritis Rheum. 2004;50:S596.
35. Lapteva L, Nowak M, Yarboro CH, et al. Anti-N-methyl-D-aspartate receptor antibodies, cognitive dysfunction, and depression in systemic lupus erythematosus. Arthritis Rheum. 2006;54:2505-14.
36. Kowal C, Degiorgio LA, Lee JY, et al. Human lupus autoantibodies against NMDA receptors mediate cognitive impairment. Proc Natl Acad Sci U S A. 2006;103:19854-9.
37. Futrell N, Schultz LR, Millikan C. Central nervous system disease in patients with systemic lupus erythematosus. Neurology. 1992;42:1649-57.
38. Csepany T, Bereczki D, Kollar J, et al. MRI findings in central nervous system systemic lupus erythematosus are associated with immunoserological parameters and hypertension. J Neurol. 2003;250:1348-54.
39. Provenzale JM, Heinz ER, Ortel TL, et al. Antiphospholipid antibodies in patients without systemic lupus erythematosus: Neuroradiologic findings. Radiology. 1994;192:531-7.
40. Toubi E, Khamashta MA, Panarra A, Hughes GR. Association of antiphospholipid antibodies with central nervous system disease in systemic lupus erythematosus. Am J Med. 1995;99:397-401.
41. Tietjen GE, Day M, Norris L, et al. Role of anticardiolipin antibodies in young persons with migraine and transient focal neurologic events: A prospective study.[see comment]. Neurology. 1998;50:1433-40.
42. Sailer M, Burchert W, Ehrenheim C, et al. Positron emission tomography and magnetic resonance imaging for cerebral involvement in patients with systemic lupus erythematosus. J Neurol. 1997;244:186-93.
43. Schmidt R, Auer-Grumbach P, Fazekas F, et al. Anticardiolipin antibodies in normal subjects, neuropsychological correlates and MRI findings.[see comment]. Stroke. 1995;26:749-54.
44. Appenzeller S, Rondina JM, Li LM, et al. Cerebral and corpus callosum atrophy in systemic lupus erythematosus. Arthritis Rheum. 2005;52:2783-9.
45. Abreu MR, Jakosky A, Folgerini M, et al. Neuropsychiatric systemic lupus erythematosus: Correlation of brain MR imaging, CT, and SPECT. Clin Imaging. 2005;29:215-21.
46. Otte A, Weiner SM, Peter HH, et al. Brain glucose utilization in systemic lupus erythematosus with neuropsychiatric symptoms: A controlled positron emission tomography study.[see comment]. Eur J Nucl Med. 1997;24:787-91.
47. Weiner SM, Otte A, Schumacher M, et al. Diagnosis and monitoring of central nervous system involvement in systemic lupus erythematosus: Value of F-18 fluorodeoxyglucose PET. Ann Rheum Dis. 2000;59:377-85.
48. Chinn RJ, Wilkinson ID, Hall-Craggs MA, et al. Magnetic resonance imaging of the brain and cerebral proton spectroscopy in patients with systemic lupus erythematosus. Arthritis Rheumatism. 1997;40:36-46.